Anti-Alpha-Synuclein Therapeutic Vaccines

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO:

• 35 (PaDre), SEQ ID NO:
• 36 (P2), SEQ ID NO:
• 37 (P30), SEQ ID NO:
• 21 (SAT13), SEQ ID NO:
• 22 (SAT15), SEQ ID NO:
• 23 (SAT17), SEQ ID NO:
• 24, SEQ ID NO:
• 25, SEQ ID NO:
• 26, SEQ ID NO:
• 27 and/or any combination thereof.

The liposomal vaccine composition of any one of the preceding claims, wherein the peptide comprising a T-cell epitope comprises, consists essentially of or consists of an amino acid sequence selected from the group consisting of SEQ ID NO:

• 29 (SAT42), SEQ ID NO:
• 30 (SAT43), SEQ ID NO:
• 31 (SAT44), SEQ ID NO:
• 32 (SAT47), SEQ ID NO:
• 35 (PaDre), SEQ ID NO:
• 36 (P2) and SEQ ID NO:
• 37 (P30), or a close sequence analogue thereof.

A liposomal vaccine composition comprising:

• d. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO:
• 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO:12,
• e. a peptide comprising a T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:
• 24, and/or SEQ ID NO:
• 25, and/or SEQ ID NO:
• 27 and
• f. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand, preferably monophosphoryl lipid A (MPLA), and/or a toll-like receptor 9 ligand, preferably CpG.

A liposomal vaccine composition comprising:

• g. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO:
• 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO:12,
• h. a peptide comprising a T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:
• 46, and/or SEQ ID NO:
• 25, and/or SEQ ID NO:
• 27 and
• i. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand, preferably monophosphoryl lipid A (MPLA), and/or a toll-like receptor 9 ligand, preferably CpG.

A liposomal vaccine composition comprising:

• a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID No:
• 4, SEQ ID NO:
• 5 or SEQ ID NO:
• 12;
• and
• b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO:
• 32 (SAT47) or a close sequence analogue thereof;
• and
• c. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand;
• and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA).

A liposomal vaccine composition comprising:

• a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID No:
• 4, SEQ ID NO:
• 5 or SEQ ID NO:
• 12;
• and
• b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO:
• 33 (SAT58);
• and
• c. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand;
• and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA).

A liposomal vaccine composition comprising:

• a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO:
• 2,
• b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO:
• 32 (SAT47) or a close sequence analogue thereof;
• and
• c. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand and/or a toll-like receptor 9 ligand;
• and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA), wherein the toll-like receptor 9 ligand comprises CpG.

A liposomal vaccine composition comprising:

• a. a peptide antigen displayed on the surface of the liposome, which comprises, consists essentially of or consists of an amino acid sequence SEQ ID NO:
• 2,
• b. a peptide comprising a T-cell epitope which comprises, consists essentially of or consists of the amino acid sequence of SEQ ID NO:
• 33 (SAT58) and
• c. an adjuvant;
• wherein the adjuvant comprises a toll-like receptor 4 ligand and/or a toll-like receptor 9 ligand;
• and wherein the toll-like receptor 4 ligand comprises monophosphoryl lipid A (MPLA), wherein the toll-like receptor 9 ligand comprises CpG.